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Summary
Background Catheter-associated urinary tract infection (CAUTI) is a major preventable cause of harm for patients in 
hospital. We aimed to establish whether short-term routine use of antimicrobial catheters reduced risk of CAUTI 
compared with standard polytetraﬂ uoroethylene (PTFE) catheterisation.
Methods In our parallel, three group, multicentre, randomised controlled superiority trial, we enrolled adults (aged 
≥16 years) requiring short-term (≤14 days) catheterisation at 24 hospitals in the UK. Participants were randomly 
allocated 1:1:1 with a remote computer allocation to receive a silver alloy-coated catheter, a nitrofural-impregnated 
catheter, or a PTFE-coated catheter (control group). Patients undergoing unplanned catheterisation were also included 
and consent for participation was obtained retrospectively. Participants and trial staﬀ  were unmasked to treatment 
assignment. Data were collected by trial staﬀ  and by patient-reported questionnaires for 6 weeks after randomisation. 
The primary outcome was incidence of symptomatic urinary tract infection for which an antibiotic was prescribed by 
6 weeks. We postulated that a 3·3% absolute reduction in CAUTI would represent suﬃ  cient beneﬁ t to recommend 
routine use of antimicrobial catheters. This study is registered, number ISRCTN75198618.
Findings 708 (10%) of 7102 randomly allocated participants were not catheterised, did not conﬁ rm consent, or 
withdrew, and were not included in the primary analyses. Compared with 271 (12·6%) of 2144 participants in the 
control group, 263 (12·5%) of 2097 participants allocated a silver alloy catheter had the primary outcome (diﬀ erence 
–0·1% [95% CI –2·4 to 2·2]), as did 228 (10·6%) of 2153 participants allocated a nitrofural catheter (–2·1% [–4·2 to 
0·1]). Rates of catheter-related discomfort were higher in the nitrofural group than they were in the other groups.
Interpretation Silver alloy-coated catheters were not eﬀ ective for reduction of incidence of symptomatic CAUTI. The 
reduction we noted in CAUTI associated with nitrofural-impregnated catheters was less than that regarded as 
clinically important. Routine use of antimicrobial-impregnated catheters is not supported by this trial.
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Introduction
Urinary tract infection associated with indwelling cath-
eters that drain urine during and after surgery or critical 
illness is the second most common cause of hospital-
acquired infection worldwide. Conservative estimates 
suggest 145 000 adults were aﬀ ected in the USA in 20101–3 
and 47% of newly catheterised patients in the Philippines 
develop such an infection.4 Catheter-associated urinary 
tract infection (CAUTI) causes avoidable morbidity and 
increased health-care costs in high-income and de-
veloping countries.5,6 Implementation of evidence-based 
prevention strategies such as avoidance of catheter use, 
aseptic catheter insertion, and shortened duration of 
catheterisation7,8 have been associated with a 50% re-
duction in CAUTI in hospitals.3,9 Alternatively, catheters 
can be made with antimicrobial coatings that delay 
bacterial colonisation; two widely available examples are 
a silver alloy-coated latex catheter and a nitrofural-
impregnated silicone catheter, which both inhibit urin ary 
pathogens.10 A Cochrane Review11 reported that, although 
these devices can reduce bacterial contam ination of 
urine, their usefulness against symptomatic CAUTI and 
thus avoidance of the need for antibiotic treatment was 
uncertain. Recent guidance8 called for more evidence of 
eﬀ ectiveness before routine imple mentation and empha-
sised the need to focus on clinical outcomes such as 
symptomatic urinary tract infection. We aimed to 
establish whether short-term use of antimicrobial 
catheters reduced the risk of clinical CAUTI compared 
with equivalent use of standard catheters.
Methods
Study design and participants
In our multicentre, randomised, controlled trial, we 
enrolled adults (aged ≥16 years) undergoing urethral 
catheterisation for an anticipated duration of up to 
14 days from 24 UK National Health Service (NHS) 
hospitals that provide surgical care in various specialties 
Articles
1928 www.thelancet.com   Vol 380   December 1, 2012
(appendix).12 Participants who needed planned catheter-
isation as part of standard care were identiﬁ ed by local 
researchers. Instances of unplanned catheterisation with 
an anticipated short duration were identiﬁ ed by hospital 
ward staﬀ . We used wide eligibility criteria, including 
people with diabetes and individuals treated with 
immunosuppressive drugs. Ineligible patients were 
those who had symptomatic urinary tract infection at 
baseline, had undergone urological procedures in the 
previous 7 days, or had allergies to catheter materials. 
Participants provided written, informed consent before 
randomisation apart from cases of unplanned cath-
eterisation, in which participants were randomised and 
then invited to consent when recovered suﬃ  ciently; if 
individuals declined to participate they were excluded 
from the analyses. The trial was approved by a UK NHS 
research ethics committee and overseen by trial steering 
and data monitoring committees.
Randomisation and masking
Participants were allocated through simple random-
isation in a 1:1:1 ratio to a silver alloy-coated latex catheter 
(Bardex IC, Bard Medical, Crawley, UK), a nitrofural-
impregnated silicone catheter (ReleaseNF, Rochester 
Medical, Lancing, UK), or a standard poly tetra ﬂ uoro-
ethylene (PTFE)-coated latex catheter (Bard PTFE, Bard 
7102 patients enrolled
2411 randomly allocated
a nitrofural catheter
2322 randomly allocated
a silver alloy catheter
2369 randomly allocated
a PTFE catheter
2153 included in primary
outcome analysis
2097 included in primary
outcome analysis
2144 included in primary
outcome analysis
12 died
59 declined further follow-up
188 did not respond
9 died
39 declined further follow-up
209 did not respond
11 died
50 declined further follow-up
177 did not respond
26 died
75 declined further follow-up
488 did not respond
23 died
57 declined further follow-up
526 did not respond
22 died
64 declined further follow-up
491 did not respond
42 died
78 declined further follow-up
218 did not respond
30 died
65 declined further follow-up
237 did not respond
28 died
68 declined further follow-up
241 did not respond
27 died
75 declined further follow-up
503 did not respond
23 died
57 declined further follow-up
556 did not respond
23 died
64 declined further follow-up
505 did not respond
2153 had primary outcome data2097 had primary outcome data 2144 had primary outcome data
258 excluded after
randomisation
225 excluded after
randomisation
225 excluded after
randomisation
2008 received allocated catheter*1994 received allocated catheter* 2120 received allocated catheter*
1894 completed questionnaire
at 3 days
1840 completed questionnaire
at 3 days
1906 completed questionnaire
at 3 days
1548 completed diary at 2 weeks1461 completed diary at 2 weeks 1552 completed diary at 2 weeks
1564 completed diary at 1 week1491 completed diary at 1 week 1567 completed diary at 1 week
1815 completed diary at 6 weeks1765 completed diary at 6 weeks 1807 completed diary at 6 weeks
Figure 1: Trial proﬁ le
Numbers of participants dying, declining further follow-up, or not responding are cumulative in direction of participant ﬂ ow.
See Online for appendix
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Medical; control group). The randomisation was 
implemented with a computer generated system, which 
users accessed via an automated telephone service or 
secure website to obtain the allocation sequence. We 
recorded compliance with the allocated intervention. 
Participants, clinicians, and the trial team were not 
masked to the allocated intervention because of the 
distinctive appearances of each catheter. When the period 
of catheterisation was unexpectedly longer than 14 days, 
we recorded trial data as if the catheter had been removed 
on day 14.
Procedures
The primary outcome was incidence of symptomatic 
CAUTI, deﬁ ned as the presence of participant-reported 
symptoms of urinary tract infection and clinician pre-
scription of antibiotic for a urinary tract infection at any 
time up to 6 weeks after randomisation. Secondary 
outcomes included incidence of microbiologically con-
ﬁ rmed symptomatic CAUTI, which was deﬁ ned as the 
primary outcome and a positive urine culture; incidence 
of bacteriuria up to 3 days after catheter removal; 
changes in health-related quality of life during the 
6 weeks of trial participation; and urethral discomfort 
related to catheterisation.
Local trial staﬀ  collected outcomes data from clinical 
records during hospitalisation and from self-completed 
participant questionnaires or diaries 3 days after catheter 
removal, 1–2 weeks after catheter removal, and 6 weeks 
after randomisation. Participant questionnaires included 
questions about symptoms of urinary tract infection, 
catheter discomfort (mild, moderate, or severe), use of 
antibiotics, and a generic health-related quality of life 
measure, EQ-5D.13 This scale divides health status into ﬁ ve 
dimensions (mobility, self care, usual activities, pain and 
comfort, and anxiety and depression).13 Each of these 
dimensions has three levels and therefore there are 
243 possible health states. We used utility scores to 
calculate quality-adjusted life-years by multiplying the time 
spent in each health state by the utility score for that state.14 
We veriﬁ ed participant reports of an episode of CAUTI 
after the end of hospital visits by contacting their primary 
care physician to conﬁ rm prescription of an antibiotic for 
urinary tract infection. Midstream voided urine samples or 
samples of urine taken directly from the catheter were 
collected at baseline, up to 3 days after catheter removal, 
and if feasible at the time of CAUTI. Samples were 
analysed according to micro biology laboratory protocols in 
UK NHS hospitals with a positive result deﬁ ned as 
bacterial counts of 10 000 colony-forming units (cfu) per mL 
or more of no more than two microorganisms.
Statistical analysis
Because a high degree of beneﬁ t would be needed to 
change routine clinical practice, we speciﬁ ed a 3·3% 
absolute reduction on the basis of estimated incidence 
in the control group of 11% (30% relative reduction; 
odds ratio [OR] 0·67). With 90% power and 2·5% 
signiﬁ cance level to account for the two comparisons, 
and allowing for an attrition rate of 15%, we needed to 
recruit 2345 participants in each group (7035 participants 
overall). Two comparisons of equal importance were 
tested in the trial: silver alloy catheters versus PTFE 
catheters and nitrofural catheters versus PTFE catheters. 
We assessed urinary tract infection outcomes with 
logistic regression and summarised ﬁ ndings as absolute 
percentage risk diﬀ erences and ORs, both with 95% CIs 
calculated as 97·5% conﬁ dence intervals to adjust for 
the two comparisons. For the primary analysis, p=0·025 
was regarded as signiﬁ cant. We analysed all included 
participants in their allocated group irrespective of the 
catheter received, according to intention-to-treat prin-
ciples, and assumed participants did not have a symp-
tomatic CAUTI unless they met the primary outcome 
criteria. We report outcomes from an unadjusted model 
and an adjusted model that corrected for age, sex, 
comorbidities, indication for catheterisation, and anti-
biotic use before catheterisation. We did a sensitivity 
analysis with the recruiting hospital as a random eﬀ ect. 
We examined the inﬂ uence of factors that aﬀ ect the risk 
of CAUTI on the reported eﬀ ectiveness of the experi-
mental catheters compared with control with tests for 
Silver alloy 
catheter 
(n=2097)
Nitrofural 
catheter 
(n=2153)
PTFE catheter 
control 
(n=2144)
Age, years 59 (16) 59 (16) 59 (16)
Sex, female 1319 (63%) 1333 (62%) 1325 (62%)
Unplanned catheterisation 94 (5%) 94 (4%) 89 (4%)
Comorbidity associated with increased CAUTI risk
Urological disorder 196/2084 (9%) 214/2138 (10%) 214/2136 (10%)
Diabetes 207/2084 (10%) 197/2138 (9%) 216/2136 (10%)
Immunosuppression* 144/2084 (7%) 135/2138 (6%) 151/2136 (7%)
Antibiotics ≤7 days before randomisation 370 (18%) 396 (18%) 385 (18%)
Prophylactic antibiotics before surgical 
procedure
1529 (73%) 1537 (71%) 1547 (72%)
Antibiotics during period of catheterisation 
(unrelated to CAUTI)
533 (25%) 511 (24%) 474 (22%)
Antibiotics after catheter removal (unrelated 
to CAUTI)
193 (9%) 178 (8%) 204 (10%)
Baseline urine sample
Midstream urine specimen 1709/2002 (85%) 1735/2074 (84%) 1721/2057 (84%)
Catheter urine specimen 293/2002 (15%) 339/2074 (16%) 336/2057 (16%)
Baseline bacterial growth
No reported growth 1830/1998 (92%) 1923/2071 (93%) 1901/2054 (93%)
≥10 000 cfu per mL 168/1998 (8%) 148/2071 (7%) 153/2054 (7%)
Duration of catheterisation, days 2 (1–3) 2 (1–3) 2 (1–3)
Prolonged catheterisation >14 days 73 (3%) 79 (4%) 67 (3%)
Duration of hospital admission, days 6 (3–8) 6 (3–9) 6 (3–9)
Data are mean (SD), n (%), n/number with available data (%), or median (IQR). PTFE=polytetraﬂ uoroethylene. 
CAUTI=catheter-associated urinary tract infection. cfu=colony-forming unit. *Immunosuppression was deﬁ ned as 
current receipt of immunosuppressive therapy with corticosteroids, methotrexate, or chemotherapy drugs.
Table 1: Baseline characteristics
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interaction at the 1% signiﬁ cance level because of their 
exploratory nature. We did a post-hoc eﬀ ect modiﬁ cation 
sensitivity analysis to explore any potential eﬀ ects of 
duration of catheterisation on reported eﬀ ectiveness. All 
subgroup and treatment-eﬀ ect modiﬁ cation analyses 
were done with the same generalised linear modelling 
framework as the main analyses. Responses to the 
EQ-5D were plotted as mean (SD) at 3 days, 1 week, and 
2 weeks after catheter removal, and at 6 weeks after 
randomisation, and we assessed changes by calculating 
the area under the curve. We explored sensitivity to 
missing data with the missing at random assumption, 
but did not impute data. We analysed all outcomes 
related to symptoms and catheter-associated discomfort 
with ordered logit models suitable for ordinal outcome 
data. Analyses were done with SAS version 9.2 and Stata 
version 11.
This study is registered, number ISRCTN75198618.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. RP, TL, GM, MK, GMc, CB, LV, and 
JN’D had full access to data collected for the trial, and 
JN’D and RP had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between July 23, 2007, and Oct 15, 2010, we enrolled 
7102 patients. 430 of these patients did not provide 
retrospective consent or withdrew their consent before 
catheterisation and were excluded from the primary 
analysis. 278 other participants who were ran domly 
allocated a catheter and consented to study inclusion 
became ineligible predominantly because they did not 
undergo urethral catheterisation owing to changed clinical 
care decisions. We included 6394 (90%) of 7102 enrolled 
participants in the main analyses, including 520 (8%) 
who provided retrospective consent after unplanned 
Silver alloy catheter Nitrofural catheter PTFE catheter control
Symptomatic antibiotic-treated UTI within 6 weeks of randomisation (primary outcome)
Incidence 263/2097 (12·5%) 228/2153 (10·6%) 271/2144 (12·6%)
Absolute risk diﬀ erence (95% CI) vs control –0·1% (–2·4 to 2·2) –2·1% (–4·2 to 0·1) ··
Unadjusted odds ratio (95% CI) 0·99 (0·81 to 1·22; p=0·92) 0·82 (0·66 to 1·01; p=0·037) ··
Adjusted odds ratio (95% CI) 0·96 (0·78 to 1·19; p=0·69) 0·81 (0·65 to 1·01; p=0·031) ··
Symptomatic antibiotic-treated UTI up to 6 weeks after randomisation associated with positive urine culture (≥10 000 cfu per mL)
Incidence n (%) 105/2097 (5·0%) 69/2153 (3·2%) 99/2144 (4·6%)
Absolute risk diﬀ erence (95% CI) vs control 0·4% (–1·2 to 1·9) –1·4% (–2·7 to –0·1) ··
Unadjusted odds ratio (95% CI) 1·08 (0·78 to 1·52; p=0·55) 0·68 (0·48 to 0·99; p=0·017) ··
Adjusted odds ratio (95% CI) 1·09 (0·78 to 1·51; p=0·58) 0·68 (0·47 to 0·98; p=0·019) ··
Symptomatic or asymptomatic bacteriuria detected by urine culture up to 3 days after catheter removal (≥10 000 cfu per mL)
Incidence n (%) 310/1785 (17·4%) 249/1846 (13·5%) 321/1839 (17·5%)
Absolute risk diﬀ erence (95% CI) vs control –0·1% (–3·2 to 2·8) –4·0% (–6·7 to –1·2) ··
Unadjusted odds ratio (95% CI) 0·99 (0·82 to 1·21; p=0·94) 0·74 (0·60 to 0·91; p=0·001) ··
Adjusted odds ratio (95% CI) 0·99 (0·81 to 1·21; p=0·89) 0·73 (0·59 to 0·90; p=0·001) ··
Self-reported participant discomfort ratings with catheter in place
Incidence of any discomfort 322/1829 (17·6%) 496/1879 (26·4%) 396/1889 (21·0%)
Absolute risk diﬀ erence (95% CI) vs control –3·4% (–6·4 to –0·4) 5·4% (2·2 to 8·7) ··
Odds ratio of experiencing discomfort (95% CI) 0·81 (0·67 to 0·98) 1·35 (1·13 to 1·62) ··
Self-reported participant discomfort ratings for catheter removal
Incidence of any discomfort 521/1817 (28·7%) 707/1867 (38·9%) 499/1881 (26·5%)
Absolute risk diﬀ erence (95% CI) vs control 2·2% (–1·3 to 5·6) 11·3% (7·8 to 14·9) ··
Odds ratio of experiencing discomfort (95% CI) 1·11 (0·94 to 1·31) 1·69 (1·44 to 1·97) ··
Absolute risk diﬀ erences derived from logistic regression models with the δ method. Adjusted models were corrected for age, sex, comorbidity, indication for catheterisation, 
and antibiotic use before catheterisation. cfu=colony-forming unit. PTFE=polytetraﬂ uoroethylene. UTI=urinary tract infection. 
Table 2: Primary and secondary trial outcomes
Fixed eﬀ ects Random eﬀ ects
Silver alloy vs PTFE control
Unadjusted odds ratio 0·99 (0·81–1·22; p=0·92) 1·00 (0·84–1·22; p=0·88)
Adjusted odds ratio 0·96 (0·78–1·19; p=0·69) 0·99; (0·81–1·20; p=0·88)
Nitrofural vs PTFE control
Unadjusted odds ratio 0·82 (0·66–1·01; p=0·037) 0·83 (0·69–1·02; p=0·039)
Adjusted odds ratio 0·81 (0·65–1·01; p=0·031) 0·83 (0·68–1·02; p=0·045)
Data are odds ratio (95% CI; p value). PTFE=polytetraﬂ uoroethylene.
Table 3: Sensitivity analysis of interaction between recruiting hospital and primary outcome
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catheterisation. 272 (4%) of 6394 participants included 
in the analysis did not receive the allocated catheter 
because clinical staﬀ  substituted an alternative catheter 
(ﬁ gure 1). Reasons for catheter isation were recorded for 
6296 participants; 5966 (95%) required perioperative 
monitor ing of urine output and 277 (5%) had urinary 
retention. The proportion of participants in the care of 
diﬀ erent specialties recruiting to the trial was balanced 
across the three groups (appen dix). Baseline characteristics 
(table 1) and response rates to postal questionnaires 
(ﬁ gure 1) were much the same between groups. We 
obtained primary outcome data for the main analyses for 
all but one non-responder (in the control group) for whom 
we assumed that no CAUTI occurred.
Incidence of symptomatic CAUTI up to 6 weeks after 
randomisation did not diﬀ er signiﬁ cantly between 
groups (table 2). A sensitivity analysis incorporating 
recruiting hospital gave almost the same results (table 3). 
No patients were reported to have been admitted to 
intensive care or died because of a CAUTI. Patients in 
the three groups did not diﬀ er in terms of duration of 
catheter use and length of hospital stay (table 1). We did 
not note any interactions between eﬀ ectiveness of the 
antimicrobial catheters and presence of risk factors 
for CAUTI (ﬁ gure 2). Longer catheter duration was 
associated with increased rate of CAUTI in all three trial 
groups but the statistical model showed no signiﬁ cant 
interaction between catheter duration and the silver alloy 
versus control comparison (p=0·83) and the nitrofural 
versus control comparison (p=0·19; ﬁ gure 3). Table 4 
shows the time of occurrence of CAUTI relative to 
catheter removal. The nitrofural catheter used in the trial 
was associated with a reduced incidence of micro-
biologically proven symptomatic CAUTI (p=0·02) and a 
lower rate of bacteriuria (p=0·001), but also greater 
participant-reported discomfort during use and at 
removal (table 2). Health statuses did not diﬀ er between 
trial groups during follow-up (table 5).
Discussion
We aimed to establish whether short-term use of either 
of two available antimicrobial catheters was clinically 
eﬀ ective in reducing CAUTI compared with the PTFE 
control (panel). Interpretation of our ﬁ ndings depends 
on the level of beneﬁ t thought suﬃ  cient to justify 
changes in practice. From a clinical perspective and 
taking into account previously reported eﬀ ect sizes,15–17 
we regarded avoidance of one CAUTI in 30 people (3·3% 
absolute reduction) to be of beneﬁ t and powered our trial 
accordingly. Other groups, such as patients needing 
short-term catheterisation or the health-care funders 
with a restricted budget, might have required lesser or 
greater degrees of beneﬁ t.
Our best estimate of the eﬀ ectiveness of the silver alloy 
catheter compared with control suggested almost no 
diﬀ erence. The results suggest that 1000 people would 
need to receive a silver alloy catheter to prevent one 
CAUTI, with the true eﬀ ect lying between one infection 
prevented in 42 people and one infection caused in 
45 people. Because the 95% CI of the absolute risk 
diﬀ erence did not include the prestated eﬀ ect size but 
did include zero, we conclude that the silver alloy catheter 
is not eﬀ ective for prevention of CAUTI. Nevertheless, 
hospitals in the USA and UK have implemented silver 
alloy-coated catheters for routine short-term use as part 
of prevention strategies against CAUTI.17–19 This use 
began after a meta-analysis of previous trials suggested a 
relative risk of 0·54 (95% CI 0·43–0·67) for bacteriuria 
compared with standard catheters,11 which was not 
changed substantially after accounting for possible bias.20 
We felt that bacteriuria did not match closely with the 
clinical diagnosis of urinary tract infection and therefore 
used a primary patient-reported urinary tract infection 
outcome backed by clinician action of antibiotic 
prescription without requirement for microbiological 
proof, assessed for at least 4 weeks after catheter removal. 
This analysis was designed to reﬂ ect usual clinical care 
and experience of patients, with an adequate observation 
period to capture relevant events, and to fulﬁ l research 
priorities set out in international public health policy 
guide lines.7,21,22 Our secondary outcomes of micro-
biologically proven symptomatic CAUTI and bacteriuria 
at up to 3 days after catheter removal were more closely 
matched to previous trials than was our primary analysis, 
but also suggested that the silver alloy catheter was 
Figure 2: Catheter-associated urinary tract infection up to 6 weeks after randomisation for the silver alloy 
catheter versus control (A) and nitrofural catheter versus control (B)
Odds ratio (99% CI)
0·3 0·4 0·5 0·57 0·67 0·82 1 21·25 1·5 1·75 2·25 3·20·44
Odds ratio (99% CI)
0·75 (0·54–1·05)
0·91 (0·63–1·31)
0·78 (0·59–1·04)
0·93 (0·56–1·52)
0·70 (0·53–0·94)
1·27 (0·78–2·09)
0·76 (0·47–1·23)
0·84 (0·63–1·12)
0·77 (0·59–1·00)
1·24 (0·63–2·44)
≥60 years
<60 years
Female
Male
No antibiotic use in past 7 days
Antibiotic use in past 7 days
No prophylactic antibiotic use
Prophylactic antibiotic use
No bacteriuria before catheterisation
Bacteriuria before catheterisation
≥60 years
<60 years
Female
Male
No antibiotic use in past 7 days
Antibiotic use in past 7 days
No prophylactic antibiotic use
Prophylactic antibiotic use
No bacteriuria before catheterisation
Bacteriuria before catheterisation
0·89 (0·65–1·23)
1·13 (0·79–1·60)
0·95 (0·72–1·26)
1·07 (0·66–1·75)
0·92 (0·72–1·21)
1·27 (0·77–2·10)
0·90 (0·56–1·45)
1·01 (0·76–1·33)
0·91 (0·70–1·18)
1·49 (0·78–2·83)
Odds ratio (99% CI)
0·3 0·4 0·5 0·57 0·67 0·82 1
Odds ratio (99% CI)
21·25 1·5 1·75 2·25 2·5 3·20·44
A
B
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ineﬀ ective. The early change in practice made by some 
hospitals was based on incomplete evidence of 
eﬀ ectiveness that mainly came from underpowered 
studies; the contrast between the ﬁ nding of no diﬀ erence 
from a robustly designed, large, multicentre pragmatic 
trial, and initial promising ﬁ ndings from smaller 
explanatory trials has been reported previously.23
The best estimate of eﬀ ectiveness for the nitrofural 
catheter was that they would prevent one symptomatic 
CAUTI in every 48 people catheterised, but that the true 
eﬀ ect could lie between one in 24 people and no protective 
eﬀ ect at all. This estimate was less than the eﬀ ect size we 
required and the 95% CI of the absolute risk diﬀ erence 
included zero so we regarded routine use of nitrofural 
catheters for short-term catheterisation as not clinically 
beneﬁ cial. Moreover, the potential for increased 
discomfort, which was reported by about one in nine 
participants, adds to the distress of an already intimate 
invasive intervention. The estimate of eﬀ ectiveness in 
our trial was smaller than that from meta-analyses of 
previous trials8,11 and in particular contrasts with a report24 
of a relative risk for antibiotic-treated CAUTI recorded as 
a secondary outcome of 0·27 (95% CI 0·10–0·69) in 
favour of nitrofural catheters. However, use of bacteriuria 
as a primary outcome and missing data for the secondary 
outcomes in that report24 restricted useful comparison 
with our results. The contrasting lack of eﬀ ectiveness 
noted in our trial might be because of our wider eligibility 
Figure 3: Observed and ﬁ tted incidence of catheter-associated urinary tract infection up to 6 weeks after randomisation versus duration of 
catheterisation
Data are n/N (%). n=number of participants with episode of CAUTI within 6 weeks of randomisation. N=number of participants with catheter duration of speciﬁ ed 
number of days. PTFE=polytetraﬂ uoroethylene (control group). CAUTI=catheter-associated urinary tract infection.
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74/691 (11%)
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31/243 (13%)
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21/149 (14%)
8/76 (11%)
12/86 (14%)
11/78 (14%)
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12/53 (23%) 
5/38 (13%)
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8/42 (19%)
2/16 (13%)
4/18 (22%)
6/28 (21%)
4/17 (24%)
3/22 (14%)
4/18 (22%)
3/14 (21%)
1/6 (17%)
1/12 (8%)
0
1 2 3 4 5 6
Duration (days)
7 8 9 10
Predicted
Predicted
Predicted
Silver alloy 
catheter 
(n=2097)
Nitrofural 
catheter 
(n=2153)
PTFE catheter 
control 
(n=2144)
No CAUTI 1834 (87%) 1925 (89%) 1873 (87%)
CAUTI during catheterisation 34 (2%) 28 (1%) 33 (2%)
CAUTI reported before completion of week 1 diary 99 (5%) 77 (4%) 92 (4%)
CAUTI reported in week 1 or week 2 diary or on 6 week 
questionnaire
127 (6%) 122 (6%) 144 (7%)
Missing* 3 (<1%) 1 (<1%) 2 (<1%)
CAUTI=catheter-associated urinary tract infection. PTFE=polytetraﬂ uoroethylene. *Participants whose catheterisation 
status could not be ascertained.
Table 4: Timing of report of CAUTI relative to catheterisation status
Silver alloy catheter 
(n=2097)
Nitrofural catheter 
(n=2153)
PTFE catheter control 
(n=2144)
Available 
data (n)
Score Available 
data (n)
Score Available 
data (n)
Score
Baseline (before randomisation) 2076 0·72 (0·29) 2127 0·72 (0·29) 2123 0·72 (0·30)
3 days after catheter removal 1801 0·58 (0·28) 1860 0·59 (0·27) 1871 0·59 (0·27)
1 week after catheter removal 1308 0·60 (0·29) 1363 0·62 (0·27) 1366 0·61 (0·27)
2 weeks after catheter removal 1328 0·69 (0·27) 1405 0·70 (0·26) 1398 0·70 (0·25)
6 weeks after randomisation 1665 0·78 (0·24) 1705 0·78 (0·24) 1721 0·80 (0·23)
Data are n or mean (SD). Higher scores show better health statuses. PTFE=polytetraﬂ uoroethylene.
Table 5: Participant health state measured by responses to the EQ-5D questionnaire
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criteria, shorter cath eter duration, and pragmatic design. 
Our results for microbiological CAUTI and bacteriuria 
were suggestive of a relevant antimicrobial eﬀ ect, but 
this might be oﬀ set by public health concerns about 
widespread use of anti microbial drugs. Nitrofuran-based 
antimicrobial drugs are less prone to development of 
bacterial resistance,25 although we did not monitor this 
factor in our trial. The silicone material of manufacture 
might have contributed to greater antimicrobial eﬀ ect 
compared with the latex control catheter, but we did not 
explore this because we aimed to test the eﬀ ectiveness of 
the device as an available technology and thus rejected 
the option of inclusion of a standard silicone catheter as 
a second control group.
We pragmatically designed our trial to assess clinical 
eﬀ ectiveness of two widely available antimicrobial cath-
eters. We aimed to resolve uncertainty about the beneﬁ t 
of antimicrobial catheters for short-term use, focusing 
on the clinically relevant outcome of symptomatic 
urinary tract infection treated with antibiotics rather than 
microbiologically deﬁ ned bacteriuria.8 We believed that 
our chosen primary outcome would be measurable and 
represent a clinically important event that shows patients’ 
experience. This deﬁ nition and our successful attribution 
of the outcome across the trial population allowed strong 
and practically useful conclusions to be made about the 
clinical eﬀ ectiveness of antimicrobial catheters. We also 
adopted a pragmatic approach to recruitment, which 
ensured that participants were repre sentative of patients 
needing short-term catheterisation in hospital, with 
particular emphasis on those individuals who were 
admitted for elective surgery (the population most often 
requiring this intervention) meaning that the results can 
be readily generalised. The wide spectrum of hospital 
types, specialties, and surgical procedures that we 
included was protective against selection bias but we did 
not recruit patients admitted directly to intensive care 
units and the number of eligible patients identiﬁ ed and 
recruited from acute medical wards was small.
The trial had 90% power to detect a clinically mean-
ingful beneﬁ t from routine use of the antimicrobial 
catheters. For both comparisons, the central estimate 
was less than the eﬀ ect size required and the 95% CI of 
the absolute risk diﬀ erence included zero. The results 
therefore allow the ﬁ rm conclusion that the silver alloy 
catheter and the nitrofural catheter did not diﬀ er in 
terms of eﬀ ectiveness from control. Assuming that our 
hypothesised eﬀ ect size of 3·3% and CAUTI incidence 
with a standard catheter of 11% were correct, we had 
about 10% chance of a type II error (ie, to wrongly 
conclude that the catheters are ineﬀ ective). Other 
investigations might have regarded a lesser absolute 
diﬀ erence in CAUTI risk to be worth exploring and 
powered the study accordingly. However, we are conﬁ dent 
that the 3·3% diﬀ erence we set out to identify is a 
plausible estimate of the minimum beneﬁ t needed to 
change routine practice.
To minimise misclassiﬁ cation of participants’ self-
report of urinary tract infection, we successfully 
resolved any missing data and conﬁ rmed CAUTI 
through veri ﬁ cation of clinician prescription of anti-
biotics. Because of the size of the trial and available 
resources, we could not independently verify that 
participants reporting no CAUTI after discharge from 
hospital had not received a prescription of antibiotic for 
urinary tract infection. We believe that misclassiﬁ cation 
of absence of CAUTI was unlikely to diﬀ er between 
trial groups because decisions by participants not to 
report symptoms and treatment decisions by primary 
care clinicians would not be inﬂ uenced by the type of 
catheter used. Some episodes of community-acquired 
urinary tract infections were prob ably captured, 
especially for participants with short catheter duration. 
However recent catheterisation would remain a risk 
factor and there was no interaction between duration 
and eﬀ ectiveness. Telephone and internet-based trial 
entry with computer-generated simple random isation 
reduced risk of allocation bias. Withdrawals after 
randomisation were mainly attrib utable to patients not 
receiving a catheter because of changes to treatment 
decisions or refusal to participate after unplanned 
catheterisation, which were factors unrelated to allo-
cated catheter type. We could not mask the allocated 
catheter, but clinical staﬀ  who inserted the catheter 
were unlikely to be involved in decisions about timing 
of removal or prescription of antibiotics for CAUTI.
We used 10 000 cfu per mL or more as the threshold for 
a positive urine culture because this value is consistently 
reported by participating hospital laboratories. However, 
this cutoﬀ  might have resulted in higher absolute rates 
for microbiologically driven outcomes than is noted in 
studies that use the more common cutoﬀ  of 100 000 cfu 
Panel: Research in context
Systematic review
This trial was commissioned because a Cochrane Review11 (published in 2004 and 
updated in 2008) reported that although the summarised evidence from published 
randomised trials suggested that antimicrobial catheters reduced the rate of 
microbiological bacteriuria, no evidence existed for an associated reduction in 
morbidity related to symptomatic catheter-associated urinary tract infection (CAUTI). 
This suggestion was conﬁ rmed by a further systematic review and reappraisal of the 
Cochrane meta-analysis published by the US Centers for Disease Control and Prevention 
in 2009,1 which emphasised the need for large pragmatic trials using symptomatic 
CAUTI as the primary outcome.
Interpretation
The pragmatic design of our trial, large sample size, and use of primary outcomes 
combining perspectives from patients, clinicians, and health-care providers, provide clear 
information about the relative beneﬁ t of two widely available antimicrobial catheters. 
Our ﬁ nding that silver-alloy catheters and nitrofural-impregnated catheters do not 
provide the prestated minimum level of clinical eﬀ ectiveness will allow better decisions to 
be made about use of these devices in health care.
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per mL. We did not monitor use of other CAUTI 
prevention actions in participating hospitals, but noted 
no evidence for interaction between hospital and com-
parative eﬀ ectiveness. This ﬁ nding provides some 
reassurance that any possible diﬀ erences between 
institutions or individual clinicians in terms of diagnosis 
of clinical CAUTI or criteria used to initiate antibiotic 
treatment did not aﬀ ect our primary outcome. Duration 
of catheter use by most participants may have been too 
short to allow the antimicrobial eﬀ ect of the tested 
catheters to become apparent. The study was designed to 
align with routine hospital practice, and patients in this 
setting are unlikely to be able to be stratiﬁ ed as requiring 
diﬀ erent short periods of catheterisation and receive 
diﬀ erent catheters. We noted no signiﬁ cant interaction 
between catheter duration and diﬀ erences in incidence 
of CAUTI. The median duration seen in our trial was 
representative of current practice.26
Our results provide no support for the routine use of 
silver alloy-coated catheters. The nitrofural catheter was 
not eﬀ ective according to our prestated criteria and we 
would therefore regard our trial as showing no evidence 
to justify its use. However some individuals, particularly 
patients requiring short-term catheterisation, or pro-
viders seeking to reduce rates of health-care-acquired 
infections, might regard the low degree of beneﬁ t suf-
ﬁ cient and be encouraged by our ﬁ nding of signiﬁ cance 
for secondary microbiological outcomes. However, we 
caution against such alternative conclusions because 
they are not supported by the primary trial result. 
Hospitals will need to carefully consider the lack of 
eﬀ ectiveness of the tested catheters, taking into account 
diﬀ erences between the UK NHS and their own health-
care system. Organisations that have already imple-
mented use of silver-alloy catheters might be able to 
reallocate resources without loss of beneﬁ t, whereas 
organisations planning their implementation might 
wish to reconsider. Overall, patients, clinicians, and 
health-care providers probably ought to persist with 
straightforward strategies to prevent CAUTI and await 
any adjustment of guidance on CAUTI prevention in the 
light of our results before making a decision.1,7,22,27
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